Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability

Janssen Has First Combo Data, With Its Own Darzalex

Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.

Galloping jockeys and race horse toys competing for position
T-cell-recruiting bispecific antibodies are jockeying for position in multiple myeloma • Source: Alamy

Bispecific antibodies that redirect T-cells to cancer cells expressing a targeted antigen are showing impressive responses in relapsed and refractory multiple myeloma, but to date there has been little data to separate the winners from the losers. Updates at the American Society of Hematology (ASH) meeting did little to move the needle in any one bispecific antibody’s favor, but presentations during the meeting offered data and insights into how companies aim to stand out in this increasingly crowded field.

Speed of clinical trial program execution will be an important factor, as well as safety, given the cytokine-release syndrome (CRS)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.